Evaluation of adenovirus capsid labeling versus transgene expression

Virology Journal

Volumn 7, Issue , 2010, Pages

  Li, Jing ^a   Fatima, Aiman ^a   Komarova, Svetlana ^a   Ugai, Hideyo ^a   Uprety, Priyanka ^b   Roth, Justin C ^a   Wang, Minghui ^a   Oster, Robert A ^c   Curiel, David T ^a   Matthews, Qiana L ^a,d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b RANDOLPH COLLEGE   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; LUCIFERASE; VIRUS VECTOR; HYBRID PROTEIN; RECOMBINANT PROTEIN;

ADENOVIRUS; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; GENE CONSTRUCT; GENE EXPRESSION; GENE THERAPY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; SUICIDE GENE; TRANSGENE; VIRUS CAPSID; VIRUS GENOME; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR BIOLOGY; PHYSIOLOGY; REPORTER GENE; STAINING; VIROLOGY;

ADENOVIRIDAE; MIRIDAE;

ADENOVIRIDAE; CAPSID PROTEINS; GENES, REPORTER; HUMANS; LUCIFERASES; MOLECULAR BIOLOGY; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; STAINING AND LABELING; TRANSGENES; VIROLOGY;

EID: 77249147869     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-21     Document Type: Article

References (49)

1. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. MA Kay JC Glorioso L Naldini, Nat Med 2001 7 33 40 10.1038/83324 11135613
2. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. I Dmitriev V Krasnykh CR Miller M Wang E Kashentseva G Mikheeva N Belousova DT Curiel, J Virol 1998 72 9706 9713 9811704
3. Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion. QL Matthews DA Sibley H Wu J Li MA Stoff-Khalili R Waehler JM Mathis DT Curiel, Mol Imaging 2006 5 510 519 17150163
4. Fluorescently labeled adenovirus with pIX-EGFP for vector detection. LP Le M Everts IP Dmitriev JG Davydova M Yamamoto DT Curiel, Mol Imaging 2004 3 105 116 10.1162/1535350041464874 15296675
5. Use of adenovirus protein IX (pIX) to display large polypeptides on the virion - generation of fluorescent virus through the incorporation of pIX-GFP. RA Meulenbroek KL Sargent J Lunde BJ Jasmin RJ Parks, Mol Ther 2004 9 617 624 10.1016/j.ymthe.2004.01.012 15093192
6. Core labeling of adenovirus with EGFP. LP Le HN Le AR Nelson DA Matthews M Yamamoto DT Curiel, Virology 2006 351 291 302 10.1016/j.virol.2006.03.042 16678874
7. Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region. HA Ono LP Le JG Davydova T Gavrikova M Yamamoto, Cancer Res 2005 65 10154 10158 10.1158/0008-5472.CAN-05-1871 16287998
8. Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. J Li L Le DA Sibley JM Mathis DT Curiel, Virology 2005 338 247 258 10.1016/j.virol.2005.04.005 15996701
9. Novel infectivity-enhanced oncolytic adenovirus with a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer. KJ Kimball AA Rivera KR Zinn M Icyuz V Saini J Li ZB Zhu GP Siegal JT Douglas DT Curiel RD Alvarez AV Borovjagin, Mol Imaging 2009 8 264 277 19796604
10. Identification of factors that interact with the E1A-inducible adenovirus E3 promoter. HC Hurst NC Jones, Genes Dev 1987 1 1132 1146 10.1101/gad.1.10. 1132 2828166
11. Adenovirus early region 3 promoter regulation by E1A/E1B is independent of alterations in DNA binding and gene activation of CREB/ATF and AP1. M Kornuc S Kliewer J Garcia D Harrich C Li R Gaynor, J Virol 1990 64 2004 2013 2139139
12. Adenovirus E3-early promoter: sequences required for activation by E1A. DL Weeks NC Jones, Nucleic Acids Res 1985 13 5389 5402 10.1093/nar/13.14.5389 2991862
13. In vitro dynamic visualization analysis of fluorescently labeled minor capsid protein IX and core protein V by simultaneous detection. H Ugai M Wang LP Le DA Matthews M Yamamoto DT Curiel, J Mol Biol 2010 395 55 78 10.1016/j.jmb.2009.10.034 19853616
14. Activation of adenoviral gene expression by protein IX is not required for efficient virus replication. KL Sargent RA Meulenbroek RJ Parks, J Virol 2004 78 5032 5037 10.1128/JVI.78.10.5032-5037.2004 15113884
15. Development of a size-restricted pIX-deleted helper virus for amplification of helper-dependent adenovirus vectors. KL Sargent P Ng C Evelegh FL Graham RJ Parks, Gene Ther 2004 11 504 511 10.1038/sj.gt.3302107 14999222
16. Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. LP Le HN Le IP Dmitriev JG Davydova T Gavrikova S Yamamoto DT Curiel M Yamamoto, J Natl Cancer Inst 2006 98 203 214 16449680
17. Biochemical studies on adenovirus multiplication. XII. Plaquing efficiencies of purified human adenoviruses. M Green M Pina RC Kimes, Virology 1967 31 562 565 10.1016/0042-6822(67)90241-3 6022496
18. Characterization of the adenovirus proteinase: substrate specificity. A Webster S Russell P Talbot WC Russell GD Kemp, J Gen Virol 1989 70 Pt 12 3225 3234 10.1099/0022-1317-70-12-3225 2691633
19. Substrate specificity of adenovirus protease. A Ruzindana-Umunyana L Imbeault JM Weber, Virus Res 2002 89 41 52 10.1016/S0168-1702(02)00111-9 12367749
20. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer. ZB Zhu B Lu M Park SK Makhija TM Numnum JE Kendrick M Wang Y Tsuruta P Fisher RD Alvarez F Zhou GP Siegal H Wu DT Curiel, Int J Oncol 2008 32 1179 1188 18497979
21. Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer. M Sarkioja A Kanerva J Salo L Kangasniemi M Eriksson M Raki T Ranki T Hakkarainen A Hemminki, Cancer 2006 107 1578 1588 10.1002/cncr.22209 16948124
22. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. T Ranki A Kanerva A Ristimaki T Hakkarainen M Sarkioja L Kangasniemi M Raki P Laakkonen S Goodison A Hemminki, Gene Ther 2007 14 58 67 10.1038/sj.gt.3302830 16900223
23. Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. A Kanerva KR Zinn KW Peng T Ranki L Kangasniemi TR Chaudhuri RA Desmond M Wang K Takayama T Hakkarainen H Alfthan UH Stenman DT Curiel A Hemminki, Gene Ther 2005 12 87 94 10.1038/sj.gt.3302387 15385953
24. Non-invasive radioiodine imaging for accurate quantitation of NIS reporter gene expression in transplanted hearts. D Ricci AA Mennander LD Pham VP Rao N Miyagi GW Byrne SJ Russell CG McGregor, Eur J Cardiothorac Surg 2008 33 32 39 10.1016/j.ejcts.2007.09.033 17980613
25. Non-invasive imaging of firefly luciferase reporter gene expression using bioluminescence imaging in human prostate cancer models. H Li JZ Li GA Helm D Pan, Biotechnol Appl Biochem 2007 46 179 184 10.1042/BA20060081 17073822
26. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. DC MacLaren SS Gambhir N Satyamurthy JR Barrio S Sharfstein T Toyokuni L Wu AJ Berk SR Cherry ME Phelps HR Herschman, Gene Ther 1999 6 785 791 10.1038/sj.gt.3300877 10505102 (Pubitemid 29243651)
27. PET imaging of thymidine kinase gene expression in the liver of non-human primates following systemic delivery of an adenoviral vector. A Fontanellas S Hervas-Stubbs A Sampedro M Collantes A Azpilicueta I Mauleon A Paneda G Quincoces J Prieto I Melero I Penuelas, Gene Ther 2009 16 136 141 10.1038/gt.2008.122 18668147
28. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo. K Guse JD Dias GJ Bauerschmitz T Hakkarainen E Aavik T Ranki T Pisto M Sarkioja RA Desmond A Kanerva A Hemminki, Gene Ther 2007 14 902 911 10.1038/sj.gt.3302949 17377596
29. Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome. L Pham T Nakamura RA Gabriela SK Carlson KR Bailey KW Peng SJ Russell, J Gene Med 2009 11 197 206 10.1002/jgm.1289 19140107
30. Drug delivery to tumors of the central nervous system. MS Lesniak R Langer H Brem, Curr Neurol Neurosci Rep 2001 1 210 216 10.1007/s11910-001-0020-z 11898520
31. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff, N Engl J Med 2005 352 987 996 10.1056/NEJMoa043330 15758009
32. Novel advances in drug delivery to brain cancer, Technol. MS Lesniak, Cancer Res Treat 2005 4 417 428
33. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. D Kirn, Oncogene 2000 19 6660 6669 10.1038/sj.onc.1204094 11426652
34. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. D Kirn RL Martuza J Zwiebel, Nat Med 2001 7 781 787 10.1038/89901 11433341
35. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. S Worgall G Wolff E Falck-Pedersen RG Crystal, Hum Gene Ther 1997 8 37 44 10.1089/hum.1997.8.1-37 8989993
36. Conditionally replicative adenoviral vectors for malignant glioma. AM Sonabend IV Ulasov MS Lesniak, Rev Med Virol 2006 16 99 115 10.1002/rmv.490 16416455
37. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. IV Ulasov AM Sonabend S Nandi A Khramtsov Y Han MS Lesniak, Br J Cancer 2009 100 1154 1164 10.1038/sj.bjc.6604969 19277041
38. AdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy. S Idema ML Lamfers BV van DP Noske S Heukelom S Moeniralm WR Gerritsen WP Vandertop CM Dirven, J Gene Med 2007 9 1046 1056 10.1002/jgm.1113 17966130
39. Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. HC Graat MA Witlox FH Schagen GJ Kaspers MN Helder J Bras GR Schaap WR Gerritsen PI Wuisman BV van, Br J Cancer 2006 94 1837 1844 10.1038/sj.bjc.6603189 16736005
40. Cell vehicle targeting strategies. JC Roth DT Curiel L Pereboeva, Gene Ther 2008 15 716 729 10.1038/gt.2008.38 18369326
41. Armed replicating adenoviruses for cancer virotherapy. JJ Cody JT Douglas, Cancer Gene Ther 2009 16 473 488 10.1038/cgt.2009.3 19197323
42. Adenovirus type-5 entry and disassembly followed in living cells by FRET, fluorescence anisotropy, and FLIM. M Martin-Fernandez SV Longshaw I Kirby G Santis MJ Tobin DT Clarke GR Jones, Biophys J 2004 87 1316 1327 10.1529/biophysj.103.035444 15298934
43. Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX. Y Tang LP Le QL Matthews T Han H Wu DT Curiel, Virology 2008 377 391 400 10.1016/j.virol.2008.04.023 18570971
44. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo. AA Rivera M Wang K Suzuki TG Uil V Krasnykh DT Curiel DM Nettelbeck, Virology 2004 320 121 134 10.1016/j.virol.2003.11.028 15003868
45. Adenovirus Structure. PL Stewart, Adenoviral Vectors for Gene therapy, Curiel DT, Douglas JT, 2002 1 18
46. Protease of adenovirus type 2. Subcellular localization. AR Bhatti J Weber, J Biol Chem 1979 254 12265 12268 500712 (Pubitemid 10138152)
47. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Nemunaitis F Khuri I Ganly J Arseneau M Posner E Vokes J Kuhn T McCarty S Landers A Blackburn L Romel B Randlev S Kaye D Kirn, J Clin Oncol 2001 19 289 298 11208818
48. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. SO Freytag M Khil H Stricker J Peabody M Menon M Peralta-Venturina D Nafziger J Pegg D Paielli S Brown K Barton M Lu E guilar-Cordova JH Kim, Cancer Res 2002 62 4968 4976 12208748
49. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. T Reid R Warren D Kirn, Cancer Gene Ther 2002 9 979 986 10.1038/sj.cgt.7700539 12522437